The Company Core Data Sheet in Light of XML-Authoring and IDMP Master Data Implementation

Area of Science:

• Pharmacovigilance and Drug Safety
• Regulatory Affairs in Pharmaceuticals
• Information Management in Healthcare

Background:

• Labeling decisions are critical for safe and effective pharmaceutical product handling, encompassing risk assessment and user guidance.
• Existing challenges in managing product statements and risk-related information are exacerbated by evolving global regulatory landscapes.

Purpose of the Study:

• To elaborate on the fundamental business problem of pharmaceutical product labeling decisions.
• To outline the requirements for effective solutions addressing labeling complexities, particularly in light of new regulations.

Main Methods:

• Analysis of the core business problem related to pharmaceutical labeling decisions.
• Review of current practices and technological support systems (e.g., XML-based authoring).
• Consideration of the impact of Identification of Medicinal Products (IDMP) requirements.

Main Results:

• Labeling decisions dictate the inclusion or exclusion of critical product information and user advice (contraindications, precautions).
• The complexity of these decisions is amplified by worldwide Identification of Medicinal Products (IDMP) requirements.
• Existing IT solutions offer partial support but may not fully address the scope of current regulatory demands.

Conclusions:

• A comprehensive understanding of the labeling decision process is essential for pharmaceutical companies.
• There is a clear need for integrated solutions that meet the stringent requirements of global health authorities, especially IDMP.
• Future solutions must effectively manage risks and ensure accurate product information dissemination.